193 related articles for article (PubMed ID: 31301103)
1. Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes.
Suganuma Y; Shimizu T; Sato T; Morii T; Fujita H; Harada Sassa M; Yamada Y
J Diabetes Investig; 2020 Mar; 11(2):389-399. PubMed ID: 31301103
[TBL] [Abstract][Full Text] [Related]
2. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
[TBL] [Abstract][Full Text] [Related]
3. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
4. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.
Trahair LG; Horowitz M; Stevens JE; Feinle-Bisset C; Standfield S; Piscitelli D; Rayner CK; Deane AM; Jones KL
Diabetologia; 2015 Aug; 58(8):1769-78. PubMed ID: 26048234
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
[TBL] [Abstract][Full Text] [Related]
6. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
Rayner CK; Watson LE; Phillips LK; Lange K; Bound MJ; Grivell J; Wu T; Jones KL; Horowitz M; Ferrannini E; Tricò D; Frascerra S; Mari A; Natali A
Diabetes Care; 2020 Aug; 43(8):1813-1821. PubMed ID: 32471908
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
Little TJ; Pilichiewicz AN; Russo A; Phillips L; Jones KL; Nauck MA; Wishart J; Horowitz M; Feinle-Bisset C
J Clin Endocrinol Metab; 2006 May; 91(5):1916-23. PubMed ID: 16492694
[TBL] [Abstract][Full Text] [Related]
8. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
[TBL] [Abstract][Full Text] [Related]
9. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
Werner U
J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
[TBL] [Abstract][Full Text] [Related]
10. The 'early' postprandial glucagon response is related to the rate of gastric emptying in type 2 diabetes.
Huang W; Xie C; Wewer Albrechtsen NJ; Jones KL; Horowitz M; Rayner CK; Wu T
Peptides; 2023 Mar; 161():170941. PubMed ID: 36623554
[TBL] [Abstract][Full Text] [Related]
11. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
[TBL] [Abstract][Full Text] [Related]
12. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
[TBL] [Abstract][Full Text] [Related]
13. Endogenous amylin and glucagon-like peptide-1 concentrations are not associated with gastric emptying in critical illness.
Summers MJ; DI Bartolomeo AE; Zaknic AV; Chapman MJ; Nguyen NQ; Zacharakis B; Rayner CK; Horowitz M; Deane AM
Acta Anaesthesiol Scand; 2014 Feb; 58(2):235-42. PubMed ID: 24410108
[TBL] [Abstract][Full Text] [Related]
14. Plasma GLP-1 Response to Oral and Intraduodenal Nutrients in Health and Type 2 Diabetes-Impact on Gastric Emptying.
Xie C; Huang W; Watson LE; Soenen S; Young RL; Jones KL; Horowitz M; Rayner CK; Wu T
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1643-e1652. PubMed ID: 34791325
[TBL] [Abstract][Full Text] [Related]
15. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Stevens JE; Horowitz M; Deacon CF; Nauck M; Rayner CK; Jones KL
Aliment Pharmacol Ther; 2012 Aug; 36(4):379-90. PubMed ID: 22738299
[TBL] [Abstract][Full Text] [Related]
16. Effects of a D-xylose preload with or without sitagliptin on gastric emptying, glucagon-like peptide-1, and postprandial glycemia in type 2 diabetes.
Wu T; Bound MJ; Zhao BR; Standfield SD; Bellon M; Jones KL; Horowitz M; Rayner CK
Diabetes Care; 2013 Jul; 36(7):1913-8. PubMed ID: 23359361
[TBL] [Abstract][Full Text] [Related]
17. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
Kielgast U; Holst JJ; Madsbad S
Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
[TBL] [Abstract][Full Text] [Related]
18. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
[TBL] [Abstract][Full Text] [Related]
19. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
20. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
